Scientific Industries, Inc. (SI) is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment and bioprocessing systems. The company sold its Genie product line on August 7, 2025, for $9.6 million, plus an earn-out of up to $1.5 million ($1.14 million guaranteed), resulting in a gain of $5,263,400. Net loss for the year ended December 31, 2025, was $1,220,400, a substantial improvement from $6,445,400 in 2024. Loss from continuing operations decreased to $1,780,300 in 2025 from $8,023,600 in 2024. Net revenues increased by 5.4% to $5,053,800 in 2025 from $4,797,100 in 2024, primarily due to increased sales in the Torbal division (Benchtop Laboratory Equipment), offset by decreased Bioprocessing Systems sales. Gross profit percentage decreased to 25.8% in 2025 from 41.8% in 2024, mainly due to $757,400 in inventory write-offs within the Bioprocessing segment; without these, it would have been 42.6%. The company continues to invest significantly in its Bioprocessing Systems Operations for future revenue generation and expects material R&D expenditures in fiscal year 2026. A private placement on April 18, 2025, raised $1,550,000 through the sale of common stock and warrants. An accumulated deficit of $35,150,900 was reported as of December 31, 2025, and the company expects continued negative cash flows from operations in the foreseeable future. Management believes current cash and proceeds from the Genie sale are sufficient to fund operations for at least one year.